Towards Healthcare
Monoclonal Antibody for Asthma and COPD Market Trends and Companies

Monoclonal Antibody for Asthma and COPD Market Gains AI Integration Edge

The global asthma and COPD biologics market provides detailed analysis of disease-specific segments, regional distribution (NA, EU, APAC, LA, MEA), manufacturer data, competitive benchmarking, value chain stages, and trade statistics, driven by rising chronic respiratory disease prevalence and adoption of novel mAbs.

Content

  • Last Updated: 14 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The monoclonal antibody for asthma and COPD market is witnessing rapid growth, with revenues projected to surge by 2034 due to rising demand and innovative therapies.

North America is currently leading the monoclonal antibody for asthma and COPD market share 45% due to the increasing prevalence of asthma and COPD for different reasons.

Some key players include AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Regeneron Pharmaceuticals, Inc., and Novartis AG.

IgE antibodies are responsible for asthma.

WHO, NIH, USFDA, CDC, ClinicalTrials.gov, PubMed, NEJM, NIAID, GINA, NAC.
Any Questions